Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
Opaleye Management Inc. reported acquiring
The filing clarifies the price is a weighted average from multiple trades between
SANUWAVE Health, Inc. (SNWV) Form 3 shows Daniel Coyle, the company's Chief Operating Officer and an officer-director, reporting initial beneficial ownership following grants and vesting events. He directly holds 37 shares of common stock and holds options totaling 25,000 underlying shares: a 20,000-share option granted
Jeffrey Blizard, a company director of SANUWAVE Health, Inc. (SNWV), reported the acquisition of 1,342 shares of common stock through the exercise of a stock option on 09/30/2025. The option had an exercise price of $37.48 and the underlying shares are exercisable through 09/30/2030. The filing states the options were fully vested at grant date and lists the transaction as a direct ownership change. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Ian D. Miller, a director of SANUWAVE Health, Inc. (SNWV), reported a Form 4 showing the acquisition on 09/30/2025 of 1,510 stock options with an exercise price of $37.48. The options were reported as fully vested at grant and are exercisable beginning 09/30/2025 with an expiration of 09/30/203010/02/2025. The filing lists the reporting person’s address in Eden Prairie, MN and indicates the Form was filed by one reporting person.
SANUWAVE Health, Inc. reported several senior leadership changes. On September 25, 2025, Daniel Coyle was appointed Chief Operating Officer. He previously served as Vice President of Engineering and Operations since October 2024 and earlier worked as a Program Director at Nextern, a medical device manufacturer.
Effective with his promotion, Mr. Coyle’s annualized base salary was set at $225,000 and his annual cash bonus opportunity for the remainder of 2025 was set at 40% of base salary. He is also scheduled to receive options to purchase 60,000 shares of common stock on October 9, 2025, vesting in 12 equal quarterly installments.
Immediately before Mr. Coyle’s appointment, former Chief Operating Officer Peter Stegagno was moved to the role of Chief Regulatory Officer, and the board determined he no longer meets the definitions of “officer” or “executive officer” under Exchange Act rules. On the same date, President Andrew Walko was terminated without cause, effective October 24, 2025, and the company does not plan to appoint a new President at this time.
Sanuwave Health, Inc. entered into a new secured credit agreement with JPMorgan Chase Bank and other lenders. The agreement provides a $23.0 million secured term loan$5.0 million secured revolving credit facility maturing September 25, 2027, with revolver availability based on eligible accounts receivable. Proceeds, together with cash on hand, were used to repay all outstanding indebtedness under the prior Note and Warrant Purchase and Security Agreement and to pay related fees and expenses.
Loans bear interest at the Company’s option at term SOFR plus 3.50% or a base rate plus 2.50%, with quarterly amortization on the term loan and prepayment permitted without premium, subject to SOFR breakage costs. The credit facilities are secured by liens on substantially all tangible and intangible assets of the Company and its guarantor subsidiaries and include financial covenants requiring a maximum total leverage ratio of 2.50 to 1.00 and a minimum fixed charge coverage ratio of 1.25 to 1.00, along with customary covenants and events of default.
SANUWAVE Health, Inc. filed a Form S-8 to register securities for an employee benefit plan and states the registration statement is currently effective. The filing incorporates by reference the company’s Annual Report for the year ended December 31, 2024, Quarterly Reports for the quarters ended March 31, 2025 and June 30, 2025, numerous Current Reports filed in 2025, and the Form 8-A description of Common Stock. Part I disclosure documents are not filed here but will be delivered to plan participants as permitted by rule.
Sanuwave Health, Inc. reports that a third-party licensee has exercised its option to acquire a portfolio of Sanuwave, Inc. patents related to intravascular shockwave applications. The option exercise follows an exclusive license and option agreement originally entered into on March 6, 2024, which included a one-time
SANUWAVE Health, Inc. reported the results of its 2025 annual stockholder meeting and an amendment to its equity incentive plan. Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the total number of shares of common stock authorized for issuance under the plan by 500,000 shares, following prior approval by the Board on June 6, 2025.
All five director nominees—Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller and James Tyler—were elected to serve until the 2026 annual meeting. Stockholders also ratified the appointment of Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2025, approved executive compensation in an advisory vote, and indicated a preference for holding future say-on-pay votes every one year.
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 296,691 shares of SANUWAVE Health, Inc. common stock, representing 3.5% of the outstanding shares based on 8,555,616 shares outstanding as of May 5, 2025. The filing clarifies that Solas acts as an investment adviser to private funds and Mr. Golden, as portfolio manager, shares voting and dispositive power over these shares.
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Both Solas and Mr. Golden report no sole voting or dispositive power and shared voting and dispositive power over all 296,691 shares.